HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (9) Citing Articles via Google Scholar Google Scholar Articles by Arlt, W. Search for Related Content PubMed PubMed Citation Articles by Arlt, W.

Androgen therapy in women

Division of Medical Sciences, Institute of Biomedical Research, Endocrinology, Room 233, University of Birmingham, Birmingham, B15 2TT, UK

(Correspondence should be addressed to W Arlt; Email: w.arlt{at}bham.ac.uk)

Androgens in women either derive from direct ovarian production or from peripheral conversion of the adrenal sex steroid precursor, dehydroepiandrosterone, towards active androgens. Therefore, loss of adrenal or ovarian function, caused by Addison’s disease or consequent to bilateral oophorectomy, results in severe androgen deficiency, clinically often associated with a loss of libido and energy. Importantly, physiological menopause does not necessarily lead to androgen deficiency, as androgen synthesis in the ovaries may persist despite the decline in estrogen production. However, the definition of female androgen deficiency, as recently provided by the Princeton consensus statement, is not precise enough and may lead to over-diagnosis due to the high prevalence of its diagnostic criteria: androgen levels below or within the lower quartile of the normal range and concurrent sexual dysfunction. Importantly, physiological menopause is not necessarily associated with androgen deficiency and therefore does not routinely require androgen therapy. Current replacement options include transdermal testosterone administration or dehydroepiandrosterone treatment, both of which have been shown to result in significant improvements, in particular in libido and mood, while effects on body composition and muscular function are not well documented. It is important to keep in mind that the number of randomized controlled trials is still limited and that currently none of the available preparations is officially approved for use in women. Currently, androgen replacement should be reserved for women with severe androgen deficiency due to an established cause and matching clinical signs and symptoms.

This article has been cited by other articles:

				K. H. Schmitz, H. Lin, M. D. Sammel, C. R. Gracia, D. B. Nelson, S. Kapoor, T. L. DeBlasis, and E. W. Freeman Association of Physical Activity with Reproductive Hormones: The Penn Ovarian Aging Study Cancer Epidemiol. Biomarkers Prev., October 1, 2007; 16(10): 2042 - 2047. [Abstract] [Full Text] [PDF]

				G. Lombardi, N. Mondaini, A. Macchiarella, and G. del Popolo Female Sexual Dysfunction and Hormonal Status in Spinal Cord Injured (SCI) Patients J Androl, September 1, 2007; 28(5): 722 - 726. [Abstract] [Full Text] [PDF]

				R. Wangensteen, I. Rodriguez-Gomez, J. M. Moreno, M. Alvarez-Guerra, A. Osuna, and F. Vargas Effects of chronic treatment with 7-nitroindazole in hyperthyroid rats Am J Physiol Regulatory Integrative Comp Physiol, November 1, 2006; 291(5): R1376 - R1382. [Abstract] [Full Text] [PDF]

				A. M. Brooke, L. A. Kalingag, F. Miraki-Moud, C. Camacho-Hubner, K. T. Maher, D. M. Walker, J. P. Hinson, and J. P. Monson Dehydroepiandrosterone Improves Psychological Well-Being in Male and Female Hypopituitary Patients on Maintenance Growth Hormone Replacement J. Clin. Endocrinol. Metab., October 1, 2006; 91(10): 3773 - 3779. [Abstract] [Full Text] [PDF]